Chiang Mai

The trials here

What the 3 trials at this site are about, from their registry records.

Conditions

• Metastatic breast cancer2 trials
• Amyloidosis1 trial

Phase

• Phase 33 trials

Status

• Active, not recruiting2 trials
• Recruiting1 trial

Lead sponsor

• Olema Pharmaceuticals, Inc.2 trials
• Alnylam Pharmaceuticals1 trial

Running trials

• Recruiting

  Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

  NCT07085767· Phase 3· Olema Pharmaceuticals, Inc.· Source

  Contact: Olema Pharmaceuticals, Inc.

• Active, not recruiting

  OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

  NCT06016738· Phase 3· Olema Pharmaceuticals, Inc.· Source

• Active, not recruiting

  HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

  NCT04153149· Phase 3· Alnylam Pharmaceuticals· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Metastatic breast cancer1 recruiting